Pompe disease, a rare lysosomal storage disease caused by deficiency of the lysosomal acid α-glucosidase (GAA), is characterized by glycogen accumulation, triggering severe second- ary cellular damage and resulting in progressive motor handicap and premature death. Numerous disease-causing mutations in the gaa gene have been reported, but the structural effects of the pathological variants were unknown. Here we present the high-resolution crystal structures of recombinant human GAA (rhGAA), the standard care of Pompe disease. These structures portray the unbound form of rhGAA and complexes thereof with active site-directed inhibitors, providing insight into substrate recognition and the molecular framework for the rationalization of the deleterious effects of disease-causing mutations. Furthermore, we report the structure of rhGAA in complex with the allosteric pharmacolo- gical chaperone N-acetylcysteine, which reveals the stabilizing function of this chaperone at the structural level.
Structure of human lysosomal acid a-glucosidase-A guide for the treatment of Pompe disease / Roig Zamboni, Veronique; Cobucci Ponzano, Beatrice; Iacono, Roberta; Ferrara, MARIA CARMINA; Germany, Stanley; Bourne, Yves; Parenti, Giancarlo; Moracci, Marco; Sulzenbacher, Gerlind. - In: NATURE COMMUNICATIONS. - ISSN 2041-1723. - 8:1(2017), p. 1111. [10.1038/s41467-017-01263-3]
Structure of human lysosomal acid a-glucosidase-A guide for the treatment of Pompe disease
Iacono, Roberta;FERRARA, MARIA CARMINA;PARENTI, GIANCARLO;MORACCI, Marco;
2017
Abstract
Pompe disease, a rare lysosomal storage disease caused by deficiency of the lysosomal acid α-glucosidase (GAA), is characterized by glycogen accumulation, triggering severe second- ary cellular damage and resulting in progressive motor handicap and premature death. Numerous disease-causing mutations in the gaa gene have been reported, but the structural effects of the pathological variants were unknown. Here we present the high-resolution crystal structures of recombinant human GAA (rhGAA), the standard care of Pompe disease. These structures portray the unbound form of rhGAA and complexes thereof with active site-directed inhibitors, providing insight into substrate recognition and the molecular framework for the rationalization of the deleterious effects of disease-causing mutations. Furthermore, we report the structure of rhGAA in complex with the allosteric pharmacolo- gical chaperone N-acetylcysteine, which reveals the stabilizing function of this chaperone at the structural level.File | Dimensione | Formato | |
---|---|---|---|
Nature_Comm_2017.pdf
accesso aperto
Tipologia:
Versione Editoriale (PDF)
Licenza:
Dominio pubblico
Dimensione
2.25 MB
Formato
Adobe PDF
|
2.25 MB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.